ziprasidone has been researched along with Basal Ganglia Diseases in 18 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 13 (72.22) | 29.6817 |
| 2010's | 5 (27.78) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Coolen, HK; Glennon, JC; Kruse, CG; Lange, JH; Reinders, JH; Tolboom, JT | 1 |
| Beszlej, A; Bienkowski, P; Frydecka, D; Grzywacz, A; Mierzejewski, P; Samochowiec, A; Samochowiec, J; Trześniowska-Drukała, B; Tybura, P | 1 |
| Brooks, KR; Kram, BL; Kram, SJ | 1 |
| Buitelaar, JK; Grootens, KP; Kahn, RS; Peuskens, J; Sabbe, BG; Thys, E; van Veelen, NM; Verkes, RJ | 1 |
| Christodoulou, C; Douzenis, A; Gournellis, R; Lykouras, LP; Rizos, E | 1 |
| Li, YM; Ou, JJ; Wu, RR; Zhao, JP | 1 |
| Bachinsky, M; Cavus, I; Karayal, ON; Kolluri, S; Sachs, GS; Vanderburg, DG | 1 |
| Daniel, DG; Romano, SJ; Simpson, G; Weiden, PJ | 1 |
| Sathpathy, S; Winsberg, B | 1 |
| Cancro, R; Chuang, L; Jacobson, J; Lusskin, SI | 1 |
| Johnson, CE; Mason, MN; Piasecki, M | 1 |
| Dubois, D | 1 |
| Matsui-Sakata, A; Ohtani, H; Sawada, Y | 1 |
| Berg, PH; Breier, A; Cavazzoni, P; Gattaz, WF; Kane, JM; Naber, D; Roychowdhury, SM; Thakore, JH; Walker, DJ | 1 |
| Bowie, C; Green, MF; Harvey, PD; Loebel, A | 1 |
| Colasanti, A; Dragogna, F; Fiorentini, A; Mauri, MC; Papa, P; Rossattini, M; Valli, A; Volonteri, LS | 1 |
| Washburn, CF | 1 |
| Caley, CF; Cooper, CK | 1 |
3 review(s) available for ziprasidone and Basal Ganglia Diseases
| Article | Year |
|---|---|
Toxicology and overdose of atypical antipsychotic medications in children: does newer necessarily mean safer?
Topics: Antipsychotic Agents; Aripiprazole; Basal Ganglia Diseases; Benzodiazepines; Cardiomyopathies; Child; Clozapine; Diabetes Mellitus; Dibenzothiazepines; Drug Interactions; Drug Overdose; Dry Eye Syndromes; Humans; Hyperlipidemias; Hypotension; Olanzapine; Piperazines; Quetiapine Fumarate; Quinolones; Risperidone; Seizures; Thiazoles | 2005 |
Problems with CATIE. Phase 1: Looking back--what the clinician needs to know.
Topics: Antidepressive Agents, Second-Generation; Basal Ganglia Diseases; Benzodiazepines; Clinical Trials, Phase I as Topic; Cost-Benefit Analysis; Dibenzothiazepines; Humans; Olanzapine; Piperazines; Quetiapine Fumarate; Randomized Controlled Trials as Topic; Risk; Risperidone; Schizophrenia; Thiazoles | 2008 |
Ziprasidone: the fifth atypical antipsychotic.
Topics: Acute Disease; Antipsychotic Agents; Basal Ganglia Diseases; Body Weight; Headache; Humans; Injections, Intramuscular; Long QT Syndrome; Nausea; Piperazines; Randomized Controlled Trials as Topic; Schizophrenia; Thiazoles; Treatment Outcome; Weight Gain | 2002 |
7 trial(s) available for ziprasidone and Basal Ganglia Diseases
| Article | Year |
|---|---|
Pharmacogenetics of adverse events in schizophrenia treatment: comparison study of ziprasidone, olanzapine and perazine.
Topics: Adult; Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Catechol O-Methyltransferase; Dopamine Plasma Membrane Transport Proteins; Female; Genotype; GluK3 Kainate Receptor; Humans; Male; Middle Aged; Monoamine Oxidase; Olanzapine; Overweight; Perazine; Piperazines; Polymorphism, Genetic; Receptor, Serotonin, 5-HT2A; Receptors, Dopamine D2; Receptors, Kainic Acid; Schizophrenia, Paranoid; Serotonin Plasma Membrane Transport Proteins; Thiazoles; Weight Gain; Young Adult | 2014 |
Ziprasidone vs olanzapine in recent-onset schizophrenia and schizoaffective disorder: results of an 8-week double-blind randomized controlled trial.
Topics: Adult; Alanine Transaminase; Antipsychotic Agents; Aspartate Aminotransferases; Basal Ganglia Diseases; Benzodiazepines; Biperiden; Blood Glucose; Body Weight; Cholesterol; Chronic Disease; Electrocardiography; Female; Humans; Male; Muscarinic Antagonists; Olanzapine; Piperazines; Prolactin; Psychiatric Status Rating Scales; Psychometrics; Psychotic Disorders; Schizophrenia; Schizophrenic Psychology; Thiazoles; Triglycerides; Young Adult | 2011 |
Efficacy and tolerability of ziprasidone vs. olanzapine in naive first-episode schizophrenia: a 6-week, randomized, open-label, flexible-dose study.
Topics: Adult; Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Comparative Effectiveness Research; Dose-Response Relationship, Drug; Drug Monitoring; Episode of Care; Female; Humans; Male; Middle Aged; Olanzapine; Piperazines; Psychiatric Status Rating Scales; Psychotic Disorders; Schizophrenia; Schizophrenic Psychology; Thiazoles; Time Factors; Treatment Outcome; Weight Gain | 2012 |
Adjunctive oral ziprasidone in patients with acute mania treated with lithium or divalproex, part 1: results of a randomized, double-blind, placebo-controlled trial.
Topics: Administration, Oral; Adolescent; Adult; Antimanic Agents; Basal Ganglia Diseases; Bipolar Disorder; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Lithium Carbonate; Male; Middle Aged; Piperazines; Psychiatric Status Rating Scales; Thiazoles; Treatment Outcome; Valproic Acid; Young Adult | 2012 |
Improvement in indices of health status in outpatients with schizophrenia switched to ziprasidone.
Topics: Adolescent; Adult; Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Body Weight; Female; Health Status Indicators; Humans; Male; Middle Aged; Olanzapine; Piperazines; Prolactin; Psychotic Disorders; Risperidone; Schizophrenia; Thiazoles; Withholding Treatment | 2003 |
Olanzapine versus ziprasidone: results of a 28-week double-blind study in patients with schizophrenia.
Topics: Adult; Age of Onset; Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Blood Glucose; Double-Blind Method; Drug Administration Schedule; Fasting; Female; Humans; Lipids; Male; Olanzapine; Piperazines; Psychiatric Status Rating Scales; Quality of Life; Schizophrenia; Schizophrenic Psychology; Severity of Illness Index; Thiazoles; Treatment Outcome | 2005 |
Ziprasidone outcome and tolerability: a practical clinical trial with plasma drug levels.
Topics: Adult; Antipsychotic Agents; Basal Ganglia Diseases; Body Weight; Chromatography, High Pressure Liquid; Electrocardiography; Female; Humans; Male; Middle Aged; Piperazines; Schizophrenia; Thiazoles | 2007 |
8 other study(ies) available for ziprasidone and Basal Ganglia Diseases
| Article | Year |
|---|---|
Principal component analysis differentiates the receptor binding profiles of three antipsychotic drug candidates from current antipsychotic drugs.
Topics: Antipsychotic Agents; Basal Ganglia Diseases; Benzoxazines; Biogenic Monoamines; Humans; Hyperprolactinemia; Indoles; Metabolic Diseases; Phthalimides; Piperazines; Principal Component Analysis; Pyridines; Radioligand Assay; Receptors, Biogenic Amine; Weight Gain | 2007 |
Implications of atypical antipsychotic prescribing in the intensive care unit.
Topics: Adult; Aged; Antipsychotic Agents; Aripiprazole; Arrhythmias, Cardiac; Basal Ganglia Diseases; Benzodiazepines; Cohort Studies; Delirium; Disorders of Excessive Somnolence; Female; Humans; Inappropriate Prescribing; Intensive Care Units; Male; Middle Aged; Olanzapine; Patient Discharge; Piperazines; Quetiapine Fumarate; Retrospective Studies; Risperidone; Survivors; Thiazoles | 2015 |
Tardive dyskinesia in a patient treated with quetiapine.
Topics: Amisulpride; Antipsychotic Agents; Aripiprazole; Basal Ganglia Diseases; Dibenzothiazepines; Dyskinesia, Drug-Induced; Female; Humans; Middle Aged; Piperazines; Psychotic Disorders; Quetiapine Fumarate; Quinolones; Sulpiride; Thiazoles | 2009 |
Extrapyramidal symptoms in children on atypical antipsychotic drugs.
Topics: Antipsychotic Agents; Basal Ganglia Diseases; Child; Dibenzothiazepines; Female; Humans; Male; Piperazines; Quetiapine Fumarate; Thiazoles | 2003 |
Prolactin elevation with ziprasidone.
Topics: Adult; Antipsychotic Agents; Basal Ganglia Diseases; Bipolar Disorder; Comorbidity; Depression, Postpartum; Dibenzothiazepines; Female; Humans; Hyperprolactinemia; Piperazines; Quetiapine Fumarate; Risperidone; Thiazoles; Treatment Outcome | 2004 |
Ziprasidone-induced acute dystonia.
Topics: Acute Disease; Antipsychotic Agents; Basal Ganglia Diseases; Dose-Response Relationship, Drug; Drug Administration Schedule; Dystonia; Humans; Male; Middle Aged; Piperazines; Schizophrenia, Paranoid; Thiazoles | 2005 |
Pharmacokinetic-pharmacodynamic analysis of antipsychotics-induced extrapyramidal symptoms based on receptor occupancy theory incorporating endogenous dopamine release.
Topics: Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Clozapine; Controlled Clinical Trials as Topic; Dibenzothiazepines; Haloperidol; Humans; Olanzapine; Piperazines; Quetiapine Fumarate; Receptor, Serotonin, 5-HT2A; Receptors, Dopamine D2; Risperidone; Schizophrenia; Thiazoles | 2005 |
The dimensions of clinical and cognitive change in schizophrenia: evidence for independence of improvements.
Topics: Adolescent; Adult; Antipsychotic Agents; Basal Ganglia Diseases; Cognition Disorders; Female; Humans; Male; Middle Aged; Piperazines; Schizophrenia; Schizophrenic Psychology; Thiazoles | 2006 |